iPSC Therapy for Neurodegenerative Diseases

Induced Pluripotent Stem Cell (iPSC) Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>iPSC</td>
</tr>
<tr>
<td class="label">Autologous possible</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Unlimited source</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Low (auto)</td>
</tr>
<tr>
<td class="label">Differentiation</td>
<td>Comprehensive</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>High</td>
</tr>
</table>

Pathway Diagram

...

Induced Pluripotent Stem Cell (iPSC) Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>iPSC</td>
</tr>
<tr>
<td class="label">Autologous possible</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Unlimited source</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Low (auto)</td>
</tr>
<tr>
<td class="label">Differentiation</td>
<td>Comprehensive</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>High</td>
</tr>
</table>

Pathway Diagram

Knowledge graph relationships for IPSC (294 total edges in KG)

Introduction

Ipsc Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Induced pluripotent stem cell (iPSC) therapy represents a transformative approach in regenerative neurology. iPSCs are generated by reprogramming adult somatic cells (typically skin fibroblasts or blood cells) back to a pluripotent state, then differentiating them into the desired neural cell types. This technology enables patient-specific, personalized cell therapies and provides powerful disease modeling platforms. [@barker2019]

Mechanism of Action

Cell Replacement

• Differentiation into specific neuronal subtypes
• Patient-matched (autologous) or universal donor (allogeneic)
• Potential for complete functional integration

Disease Modeling

• Patient-derived [neurons](/entities/neurons) for drug screening
• Understanding of disease mechanisms
• Personalized drug response prediction

Immunomodulation

• Autologous cells reduce rejection risk
• Gene editing can enhance immune evasion
• Reduced immunosuppression requirements

Clinical Applications

Parkinson's Disease

• Dopaminergic neuron replacement
• Clinical trials initiated in Japan (2018)
• First iPSC trial for PD completed
• Long-term safety data emerging

Amyotrophic Lateral Sclerosis

• Motor neuron replacement
• Support cells ([astrocytes](/entities/astrocytes), microglia)
• Early-phase trials planned

Alzheimer's Disease

• Cholinergic neuron replacement
• Early-stage development
• Disease modeling in progress

Huntington's Disease

• Striatal neuron replacement
• Preclinical validation
• Clinical translation anticipated

Frontotemporal Dementia

• Cortical neuron replacement
• Limited preclinical data
• Research ongoing

Differentiation Protocols

Dopaminergic Neurons (for PD)

Dual-SMAD inhibition (SB431542, LDN-193189)

Floor plate induction

Floor plate patterning

Terminal differentiation

Purification and quality control

Motor Neurons (for ALS)

Dual-SMAD inhibition

Rostralization with retinoic acid

Caudalization with WNT activation

Motor neuron specification

Maturation

Cortical Neurons (for AD/FTD)

Neural rosette formation

Forebrain specification

Cortical neuron differentiation

Subtype specification

Clinical Trials

Japan PD Trial (2018-present)

• First-in-human iPSC trial
• Autologous iPSC-derived dopaminergic progenitors
• Seven patients treated
• Primary endpoint: safety
• Secondary: motor function improvement

Upcoming Trials

• Allogeneic iPSC for PD (multiple sites)
• iPSC for ALS (planned)
• iPSC for AD (early planning)

Advantages over Other Cell Therapies

Manufacturing Considerations

Quality Control

• Genomic stability screening
• Teratoma formation testing
• Potency assays
• Identity and purity testing
• Sterility and endotoxin testing

Scalability

• Scalable cell production
• Defined culture systems
• Automated manufacturing
• Cost reduction strategies

Regulatory

• Complex approval pathways
• IND-enabling studies
• Long-term follow-up requirements

Safety Profile

Known Risks

• Tumor formation (teratoma/oncoma)
• Immune reaction (allogeneic)
• Insertional mutagenesis
• Incomplete differentiation

Mitigation Strategies

• Rigorous quality control
• Safety switching (tk suicide gene)
• Gene editing for immune evasion
• Comprehensive monitoring

Research Directions

• Universal donor iPSC banks
• Gene correction in patient-derived cells
• 3D organoid approaches
• Automated manufacturing
• Combination therapies

See Also

• [Neural Stem Cell Therapy](/therapeutics/neural-stem-cell-therapy)
• [Cell Replacement Therapy](/therapeutics/cell-replacement-therapy)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-symptomatic-treatments)

Background

The study of Ipsc Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NIH - Induced Pluripotent Stem Cells](https://stemcells.nih.gov/info/2006_report.htm)
• [CiRA - Center for iPS Cell Research and Application](https://www.cira.kyoto-u.ac.jp/en/)
• [ClinicalTrials.gov - iPSC](https://clinicaltrials.gov/search?cond=neurodegenerative+iPSC)

References

Takahashi J, Strategies for bringing induced pluripotent stem cell-based therapy to the clinic (2023)

Barker RA, et al, Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease (2019)

Chen KG, et al, Clinical-grade human iPSC for disease modeling and regenerative therapy (2021)

Doi D, et al, Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell surface markers (2020)

Avior Y, et al, Pluripotent stem cells in neurodegenerative disease therapy and disease modeling (2022)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC

Related Analyses:

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC Therapy for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: